Floatz logo

Eribulin

Advanced Prostate Carcinoma

OHSU Knight Cancer InstituteSmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

114 Active assets in the Advanced Prostate Carcinoma cohort.

Asset / SponsorPhaseRating
LEUPROLIDE
Mayo Clinic
Phase 4BBB
Enzalutamide
Pfizer
Phase 4BBB
PREDNISONE TABLETS
Mayo Clinic
Phase 4BBB
Degarelix
Baptist Health South Florida
Phase 3BBB
Abiraterone Acetate
Mayo Clinic
Phase 4BBB

View all 50 →

Same molecule, other indications

Eribulin is also rated in:

Locally Recurrent Breast CancerDormant
BB
Indicative ·
70 / 100
View asset →
breast cancerDormant
BB
Indicative ·
67 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →